Beam Therapeutics posts a wider-than-expected Q2 loss. Revenues also miss estimates as it advances m

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.18 per share versus the Zacks Con

Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(1.18) per share which missed the anal

Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the Europea

Beam Therapeutics offers compelling upside, with a $2.64B market cap and a promising gene-editing pi

Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines

CAMBRIDGE, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotech

Beam Therapeutics Inc. (NASDAQ: BEAM - Get Free Report) has received an average recommendation of "M

Amova Asset Management Americas Inc. lowered its stake in Beam Therapeutics Inc. (NASDAQ: BEAM) by 1

Beam Therapeutics' growing pipeline could reward patient investors.

Prime Medicine, Inc. secured a favorable arbitration ruling against Beam Therapeutics, allowing cont

Prime Medicine Inc. (NASDAQ:PRME) said it secured a favorable, binding arbitration ruling in its dis

Gene-editing is a handy tool for developing sophisticated medicines. A new CRISPR molecule can destr

Data show high levels of short interest in 10 stocks, including Avis Budget, RH, Lucid and CleanSpar

Fresh short‑interest data for late June shows a tightly packed group of mid‑ and large‑cap names whe

Beam Therapeutics gains after the FDA clears the IND for BEAM-304 in PKU, advancing its liver-target

BEAM-304 Development Approach Has Potential to Create Transformative, One-time Therapies for the Maj

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Bioscienc

BEAM shares jump 21% in three months as promising BEAM-302 data, pipeline milestones and a cash runw

Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine

Beam Therapeutics Inc. (BEAM) Presents at RBC Capital Markets Global Healthcare Conference 2026 Tran

Beam Therapeutics NASDAQ: BEAM Chief Executive Officer John Evans said the company is advancing its

Presentation Features Additional Data from the Single-dose Cohorts of the Phase 1/2 Trial, Including

U.S. stocks were lower, Dow Jones fell 0.1% on Monday. XOMA shares rose on Ligand's plans to acq

Jim Cramer recommends buying Affirm Holdings (AFRM) on CNBC's Mad Money Lightning Round. Analyst

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potenti

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a str

  On Tuesday, 647 companies set new 52-week lows.

  During Tuesday's trading, 188 companies set new 52-week lows.

  During Thursday's session, 92 stocks hit new 52-week lows.

  During Wednesday's trading, 103 companies set new 52-week lows.

  On Wednesday, 807 companies reached new 52-week lows.

  On Friday, 1043 companies hit new 52-week lows.

  During Thursday, 849 stocks hit new 52-week lows.

  Wednesday's session saw 784 companies set new 52-week lows.

  On Friday, 431 companies hit new 52-week lows.

  On Wednesday, 160 companies hit new 52-week lows.

  During Tuesday's session, 454 stocks hit new 52-week lows.

Upgrades

Upgrades

    Before 10 a.m. ET Friday, 146 stocks hit new 52-week highs.

    This morning 158 companies set new 52-week highs.

    Monday morning saw 558 companies set new 52-week highs.

  This morning 150 companies reached new 52-week highs.